Literature DB >> 94630

Prazosin first-pass metabolism and hepatic extraction in the dog.

P Rubin, Y G Yee, M Anderson, T Blaschke.   

Abstract

The short half-life, low plasma concentrations, and extensive biotransformation of prazosin suggest that it might be subject to extensive first-pass metabolism. Bioavailability, disposition, and hepatic extraction were studied in the dog. In conscious dogs whole blood prazosin concentrations were measured after oral and intravenous administration of the drug. Anesthetized dogs were used to measure prazosin concentrations in arterial and hepatic venous blood samples drawn simultaneously. The bioavailability of prazosin was 0.38 +/- 0.11. In anesthetized dogs the hepatic extraction of prazosin was 0.47 +/- 0.08 for a predicted availability of 0.53 +/- 0.08. Pharmacokinetic parameters were similar in conscious and anesthetized animals. Following intravenous administration to conscious dogs, prazosin concentrations in whole blood declined with a fast half-life of 3.9 +/- 1.74 min and a slow half-life of 153 +/- 24 min, the volume of distribution at steady state being 48.6 +/- 15.3 liters in dogs (mean weight, 22.6 kg). We conclude that prazosin availability following oral administration is low and that first-pass hepatic metabolism is largely responsible for this. A one-compartment model adequately describes prazosin pharmacokinetics in the dog.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 94630     DOI: 10.1097/00005344-197911000-00005

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Proceeding of the British Pharmacological Society, Clinical Pharmacology Section, 16-18th December, 1980, University of London. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

2.  Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension.

Authors:  P C Rubin; L Butters; R A Low; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

3.  Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension.

Authors:  P R Mills; A P Rae; D A Farah; R I Russell; A R Lorimer; D C Carter
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

4.  Prazosin disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of prazosin.

Authors:  P Jaillon
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.